Human RCTPubMed ID: 28679801·2017

Semaglutide and Progression of Diabetic Kidney Disease (SUSTAIN-6)

Mann JFE, Orsted DD, Brown-Frandsen K, et al.

New England Journal of Medicine, 2017 · n = 3297

Key finding

Semaglutide reduced progression to macroalbuminuria or doubling of serum creatinine by 36% (HR 0.64, 95% CI 0.46-0.88, p=0.005).

Summary

Large RCT demonstrating semaglutide reduced progression of diabetic kidney disease with 36% reduction in incident or worsening nephropathy.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

SemaglutideL5

An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.

More research on Semaglutide

Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT)

New England Journal of Medicine · 2023 · Human RCT

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)

New England Journal of Medicine · 2023 · Human RCT

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)

Nature Medicine · 2022 · Human RCT

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8)

JAMA · 2022 · Human RCT

STEP 3: Semaglutide for Weight Management in Severe Obesity

New England Journal of Medicine · 2022 · Human RCT